Your GLP-1 Program Was Never Selling the Drug

Go look at what your patient can see. Novo Nordisk publishes its self-pay prices on a public page, no login, no insurance, no prior authorization. As of this writing, the oral form of Wegovy starts at $149 a month. The injectable pen runs $199 a month for a new patient's first two months and $349 after that. Medicare-eligible patients can get to $50 a month through a bridge program.

Your patient can find that page in about eleven seconds.

I have watched a lot of independent practices build weight-loss revenue over the past three years, and a meaningful share of them built it on access. Access to a molecule that was hard to get, expensive through normal channels, and available through you. That was a real business while it lasted. It is not a business anymore, and the thing that ended it was not a competitor down the street. It was the manufacturer deciding to sell direct.

The strategic question is not whether to keep offering GLP-1s. It is whether you ever knew what you were charging for.

The price you are competing against is published

Start with the actual numbers, because most owners I talk to are working from a price they heard about eighteen months ago.

Novo Nordisk's self-pay pricing through its own pharmacy currently lists the Wegovy pill starting at $149 per month for the 1.5 mg and 4 mg doses, with the 4 mg presentation available only through August 31, 2026. The pen and the higher-dose version are offered at $199 a month for a new patient's first two months, then $349 a month for standard pens and $399 for the 7.2 mg version. Medicare-eligible patients have a stated $50 per month pathway. The page states that pricing will be updated after December 31, 2026.

Two things in that paragraph matter more than the headline number.

The first is the oral formulation. An injectable creates a small but real barrier: some patients will not do needles, and the ones who will often want someone to show them how the first time. A pill removes the last practical reason a motivated, price-sensitive patient needs a clinical setting to start.

The second is that date. Pricing updates after December 31, 2026, and one dose presentation disappears at the end of this month. If your program's price is set relative to the drug's price, you are not running a pricing strategy. You are running a subscription to somebody else's pricing committee, and it re-prices at least twice a year without consulting you.

What your program actually sells

Here is the exercise I would run before touching your price list. Write down everything a patient receives from your weight-loss program. Then cross off every line the manufacturer's direct channel also provides.

What is left is your actual product. For most physician-led practices it is a short list, and it is a good one.

I pulled the program description from a physician-led practice we work with in Michigan, because it is a clean example of a program that was built as medicine rather than as distribution. What a patient gets there: a full evaluation covering health history, current medications, labs, and goals before anything is prescribed. Dose started low and titrated gradually to limit side effects. Ongoing lab monitoring. Screening for contraindications, including thyroid and pancreatitis risk. Access to the physician throughout for dose adjustments. Tirzepatide available as an alternative if semaglutide is the wrong fit.

Their own page draws the line explicitly: this is not a prescription that arrives in the mail with no follow-up.

That practice can survive $149 pills, because none of what I just listed is in the box. The mail-order channel ships a molecule. It does not check your thyroid, it does not adjust your dose when you cannot keep food down in week three, and it does not notice when the weight comes off too fast.

The practices that cannot survive it are the ones whose program was a prescription, a scale, and a monthly refill. If that describes yours, the direct channel is not a threat on the horizon. It is a strictly better version of what you sell, at a price you cannot match, and no amount of marketing fixes a product that has been made redundant.

The test I would run this week

There is a single question that sorts practices into the two groups, and it takes ten minutes.

Ask yourself what happens to your weight-loss program if the drug's price goes to zero.

If the answer is that the program collapses, you were selling distribution and the market has already repriced you. If the answer is that the program continues largely intact, because patients are paying for evaluation, titration, monitoring, and a physician who knows their history, then the drug's price is an input cost and you have been running a real service the whole time. In that case the direct channel is not your competitor. It is your supplier getting cheaper, which is a thing you should be pleased about.

Most owners have never separated those two revenue streams on paper, which is why the question lands hard. The medication and the medical management get billed as one number, so nobody knows the split.

You now have an external benchmark for one half of it. The direct channel prices the molecule between $149 and $349 a month depending on formulation, so whatever you charge above that figure, per patient per month, is what the market is currently willing to call your medical care. In my work with practices, running that subtraction is the first time most owners see their own service priced apart from their supply, and the remainder is usually smaller than they expected. That is not a reason to despair. It is the first honest number you have had on this line of business.

The generalizable lesson, and the reason I would not file this under weight loss: any revenue line whose differentiator is access to a product is a revenue line the product's owner can reclaim whenever the economics suit them. That is true of peptides, it is true of hormone therapy, and it will be true of whatever the next conference floor is excited about. Access is a rented advantage. Clinical judgment is an owned one.

What to do about it

Four moves, in order.

First, unbundle your pricing internally. Separate what you charge for the medication from what you charge for the medical program. You do not have to show patients the split. You do have to know it.

Second, reprice the program, not the drug. If the medication becomes a pass-through at something near the direct price, and your fee covers evaluation, labs, titration, and physician access, you have a defensible structure that does not move when Novo Nordisk updates a webpage in January.

Third, treat these patients as the recurring-revenue base they are, because the economics are membership economics. CT Acquisitions' 2026 valuation work puts monthly churn in this category at 5 to 10 percent, which produces a patient lifetime of roughly 10 to 20 months. A weight-loss patient who stays fourteen months at a real program fee is worth considerably more than one who buys three months of discounted vials and leaves, and buyers pay for the first kind of revenue at a different multiple than the second.

Fourth, say the difference out loud in your marketing. Not as a claim that you are better, which every practice says. As a specific description of what the mail-order box does not contain: the labs, the titration, the contraindication screening, the person who answers when week three goes badly. Patients cannot choose a difference nobody described to them, and right now most practices are competing on a price comparison they have already lost instead of on a service comparison they would win.

That fourth one is the part practices consistently underinvest in, and it is the part GrowBien exists to run.

The uncomfortable truth in all of this is that the direct-pricing move did not create a problem. It revealed one. Practices that built weight-loss revenue on medicine are fine, and some of them are better off with a cheaper input. Practices that built it on access were always going to lose that access eventually, because access was never theirs to begin with.

---

Sources and limits. Self-pay pricing figures are from Novo Nordisk's NovoCare pharmacy savings page, read on 2026-08-31; that page states its own pricing is subject to update after December 31, 2026, so re-check before quoting these numbers later. The program-design detail is first-party, drawn from the published patient-facing service description of a physician-led practice GrowBien works with in Troy, Michigan. Churn and patient-lifetime figures are from CT Acquisitions' Med Spa and Medical Aesthetic M&A Multiples Report 2026, July 2026, which cites FOCUS Investment Banking, BizBuySell, and AmSpa upstream. I referred above to compounded GLP-1 supply narrowing after the shortages were declared over; I was unable to reach FDA primary documentation at the time of writing to date-stamp that sequence, so it is stated as background rather than as a sourced claim, and no part of the argument depends on it. I did not find, and therefore do not cite, any credible published benchmark for what independent practices charge for GLP-1 programs.